ART-5803

N/A

Report date: 2026/05/15 20:01:45

Base Information

Drug NameART-5803
Drug Alias NameART-5803
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionGlutamate [NMDA] receptor modulators
TargetsGlutamate [NMDA] receptor
Therapy Area/IndicationsMental DisordersEncephalitisAnti-N-Methyl-D-Aspartate Receptor Encephalitis
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesAustraliaSouth Korea
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesArialys Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesArialys Australia Pty LtdArialys Therapeutics Inc
Inactive CompaniesN/A
Active IndicationsMental DisordersEncephalitisAnti-N-Methyl-D-Aspartate Receptor Encephalitis
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A